- KR₩97bn
- KR₩127bn
- KR₩83bn
- 57
- 54
- 40
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.38 | ||
| Price to Tang. Book | 1.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.17 | ||
| EV to EBITDA | 9.14 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.36% | ||
| Return on Equity | 15.76% | ||
| Operating Margin | 11.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 59,391.35 | 44,997.6 | 58,780.47 | 68,941.5 | 83,100.72 | n/a | n/a | 9.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -74.98 | +375.38 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Meta Biomed Co., Ltd. is a Korea-based company engaged in the manufacture of medical materials and equipment for biotechnology and dental areas. The Company mainly operates its business through three divisions: suture material division, dental division and bone material division. Its suture material division provides suture materials, such as polyglycolic acid (PGA) synthetic absorbable braids, polyglycolic acid-co-lactic acid (PGLA) absorbable braids, polydioxanone (PDO) synthetic absorbable monofilaments, polyglycolide-co-epsilon-caprolactone (PGCL) synthetic absorbable monofilaments and others. Its dental division provides dental materials and equipment, such as gutta percha cordless obturation systems, electronic apex locators, taper points, root canal sealers, root canal filling materials and others. Its bone materials division provides bone graft substitutes. It also distributes dental-related products.
Directors
- Seok Song Oh CEO (59)
- Bok Gi Cho VPR (61)
- Won Gyeong Choi VPR (59)
- Yeon Chun Yoo MDR (46)
- Seong Yil Cho OTH (61)
- Jang Hui Lee NID (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 1st, 1999
- Public Since
- April 15th, 2008
- No. of Shareholders
- 9,564
- No. of Employees
- 198
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 22,871,108
- Address
- 634, Yeonje-Ri, Osong-Eup, CHEONGJU, 28161
- Web
- https://www.meta-biomed.com/
- Phone
- +82 432181981
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 059210
Similar to 059210
Access Bio
Korea Exchange - KOSDAQ
Aligned Genetics
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
Biodyne Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:14 UTC, shares in Metabiomed Co are trading at KR₩4,240. This share price information is delayed by 15 minutes.
Shares in Metabiomed Co last closed at KR₩4,240 and the price had moved by +97.9% over the past 365 days. In terms of relative price strength the Metabiomed Co share price has outperformed the FTSE Developed Asia Pacific Index by +98.09% over the past year.
There is no consensus recommendation for this security.
The Metabiomed Co dividend yield is 0.47% based on the trailing twelve month period.
Last year, Metabiomed Co paid a total dividend of KR₩20, and it currently has a trailing dividend yield of 0.47%. We do not have any data on when Metabiomed Co is to next pay dividends.
We do not have data on when Metabiomed Co is to next pay dividends. The historic dividend yield on Metabiomed Co shares is currently 0.47%.
To buy shares in Metabiomed Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩4,240, shares in Metabiomed Co had a market capitalisation of KR₩97bn.
Here are the trading details for Metabiomed Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 059210
Based on an overall assessment of its quality, value and momentum Metabiomed Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Metabiomed Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +3.04%.
As of the last closing price of KR₩4,240, shares in Metabiomed Co were trading -0.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Metabiomed Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩4,240.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Metabiomed Co's management team is headed by:
- Seok Song Oh - CEO
- Bok Gi Cho - VPR
- Won Gyeong Choi - VPR
- Yeon Chun Yoo - MDR
- Seong Yil Cho - OTH
- Jang Hui Lee - NID